• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Exercise for Clients Taking an Anti-Obesity Medication.服用抗肥胖药物的客户的运动
ACSMs Health Fit J. 2024 May-Jun;28(3):21-26. doi: 10.1249/fit.0000000000000959.
2
Medication-Assisted Weight Loss in the Age of Obesity.肥胖时代的药物辅助减肥
J Psychosoc Nurs Ment Health Serv. 2017 Aug 1;55(8):21-26. doi: 10.3928/02793695-20170718-02.
3
Effectiveness and persistence of anti-obesity medications (liraglutide 3 mg, lorcaserin, and orlistat) in a real-world primary care setting.在真实世界的基层医疗环境中，抗肥胖药物（利拉鲁肽 3mg、lorcaserin 和奥利司他）的疗效和持久性。
Fam Pract. 2023 Dec 22;40(5-6):629-637. doi: 10.1093/fampra/cmac141.
4
Pharmacotherapy for the Treatment of Overweight and Obesity in Children, Adolescents, and Young Adults in a Large Health System in the US.美国大型医疗体系中儿童、青少年和青年超重与肥胖的药物治疗
Front Endocrinol (Lausanne). 2020 May 13;11:290. doi: 10.3389/fendo.2020.00290. eCollection 2020.
5
Navigating coverage: A qualitative study exploring the perceived impact of an insurance company policy to discontinue coverage of antiobesity medication.医保覆盖范围解读：一项定性研究，探讨保险公司停止承保抗肥胖药物政策的感知影响。
Obes Pillars. 2024 Jul 22;11:100120. doi: 10.1016/j.obpill.2024.100120. eCollection 2024 Sep.
6
Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care.基于肠促胰岛素的疗法与生活方式干预：注册营养师在肥胖症护理中不断演变的作用。
J Acad Nutr Diet. 2025 Mar;125(3):408-421. doi: 10.1016/j.jand.2024.10.023. Epub 2024 Nov 7.
7
Medications as adjunct therapy for weight loss: approved and off-label agents in use.作为减肥辅助疗法的药物：已批准和未按批准用途使用的药物
J Am Diet Assoc. 2005 Jun;105(6):948-59. doi: 10.1016/j.jada.2005.03.010.
8
Evidence-based weight loss interventions: Individualized treatment options to maximize patient outcomes.循证减肥干预措施：最大化患者结局的个体化治疗选择。
Diabetes Obes Metab. 2021 Feb;23 Suppl 1:50-62. doi: 10.1111/dom.14200. Epub 2020 Nov 24.
9
The Benefit of Healthy Lifestyle in the Era of New Medications to Treat Obesity.新药物治疗肥胖时代健康生活方式的益处
Diabetes Metab Syndr Obes. 2024 Jan 15;17:227-230. doi: 10.2147/DMSO.S447582. eCollection 2024.
10
Long-term drug treatment for obesity: a systematic and clinical review.长期药物治疗肥胖：系统评价和临床综述。
JAMA. 2014 Jan 1;311(1):74-86. doi: 10.1001/jama.2013.281361.

引用本文的文献

1
A Remotely Delivered GLP-1RA-Supported Specialist Weight Management Program in Adults Living With Obesity: Retrospective Service Evaluation.一项针对肥胖成人的远程提供的GLP-1受体激动剂支持的专科体重管理计划：回顾性服务评估
JMIR Form Res. 2025 Jun 30;9:e72577. doi: 10.2196/72577.
2
Health and Well-Being Coaching Adjuvant to GLP-1 Induced Weight Loss.健康与幸福指导辅助GLP-1诱导的体重减轻。
Am J Lifestyle Med. 2024 Nov 19:15598276241302273. doi: 10.1177/15598276241302273.
3
Knowledge and Perception of Anti-obesity Medications Among Primary Healthcare Center Visitors in Jeddah, Saudi Arabia in 2024: An Analytical Cross-Sectional Study.2024年沙特阿拉伯吉达初级医疗中心就诊者对减肥药的认知与看法：一项分析性横断面研究
Cureus. 2024 Aug 30;16(8):e68240. doi: 10.7759/cureus.68240. eCollection 2024 Aug.

本文引用的文献

1
The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities.生活方式改变与第二代抗肥胖药物的作用：比较、问题与临床机遇。
Curr Obes Rep. 2023 Dec;12(4):453-473. doi: 10.1007/s13679-023-00534-z. Epub 2023 Dec 2.
2
Physical activity in the new era of antiobesity medications.抗肥胖药物新时代的体育活动。
Obesity (Silver Spring). 2024 Feb;32(2):234-236. doi: 10.1002/oby.23930. Epub 2023 Oct 17.
3
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics.肥胖症治疗的新前沿：基于胰高血糖素样肽-1和新生营养刺激激素的疗法
Annu Rev Med. 2023 Jan 27;74:125-139. doi: 10.1146/annurev-med-043021-014919.
4
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
5
Impact of weight loss with diet or diet plus physical activity on cardiac magnetic resonance imaging and cardiovascular disease risk factors: Heart Health Study randomized trial.饮食或饮食加身体活动减肥对心脏磁共振成像和心血管疾病危险因素的影响：心脏健康研究随机试验。
Obesity (Silver Spring). 2022 May;30(5):1039-1056. doi: 10.1002/oby.23412.
6
Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.每周皮下司美格鲁肽与每日利拉鲁肽对无糖尿病超重或肥胖成年人体重的影响：STEP 8 随机临床试验。
JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.
7
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined.运动、利拉鲁肽或两者联合用于维持健康的体重减轻。
N Engl J Med. 2021 May 6;384(18):1719-1730. doi: 10.1056/NEJMoa2028198.
8
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.持续每周皮下注射司美格鲁肽与安慰剂对超重或肥胖成年人体重维持的影响：STEP 4 随机临床试验。
JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224.
9
Once-Weekly Semaglutide in Adults with Overweight or Obesity.每周一次司美格鲁肽在超重或肥胖成人中的应用。
N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
10
Feasibility of Integration of Yoga in a Behavioral Weight-Loss Intervention: A Randomized Trial.将瑜伽融入行为减肥干预的可行性：一项随机试验。
Obesity (Silver Spring). 2021 Mar;29(3):512-520. doi: 10.1002/oby.23089. Epub 2021 Feb 2.

Exercise for Clients Taking an Anti-Obesity Medication.

作者信息

Rogers Renee J

机构信息

University of Kansas Medical Center, Department of Internal Medicine, Division of Physical Activity and Weight Management.

出版信息

ACSMs Health Fit J. 2024 May-Jun;28(3):21-26. doi: 10.1249/fit.0000000000000959.

DOI:10.1249/fit.0000000000000959
PMID:39279918
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11394883/
Abstract
摘要